Role of DNA repair pathways in response to zidovudine-induced DNA damage in immortalized human liver THLE2 cells

International Journal of Biomedical Science

Volumn 9, Issue 1, 2013, Pages 18-25

  Wu, Qiangen ^a,b   Beland, Frederick A ^a   Chang, Ching Wei ^a   Fang, Jia Long ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

DNA damage and repair; Nucleotide excision repair; THLE2 cells; Zidovudine

Indexed keywords

CELL PROTEIN; PROTEIN APE1; PROTEIN GTF2H1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL IMMORTALIZATION; CELL STRAIN HEPG2; COMPLEMENTATION GROUP C GENE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; EPITHELIUM CELL; EXCISION REPAIR; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL; NORMAL HUMAN; SENSITIVITY ANALYSIS; UPREGULATION;

EID: 84875886604     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Walker VE, Poirier MC. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors. Environ. Mol. Mutagen. 2007; 48: 159-165.
2. Olivero OA, Beland FA, Fullerton NF, et al. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3'-azido-2',3'-dideoxythymidine. Cancer Res. 1994; 54: 6235-6242.
3. Ayers KM, Clive D, Tucker WE, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam. Appl. Toxicol. 1996; 32: 148-158.
4. 1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 1999; 469: 1-361.
5. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 1997; 89: 1602-1608.
6. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. Toxicol. Appl. Pharmacol. 1999; 161: 82-99.
7. NTP. NTP technical report on the toxicology and carcinogenesis studies of transplacental AZT (CAS No. 30516-87-1) in Swiss (CD-1®) mice (in utero studies). Natl. Toxicol. Program Tech. Rep. Ser. 2006; 522: 1-186.
8. Walker DM, Malarkey DE, Seilkop SK, et al. Transplacental carcinogenicity of 3'-azido-3'-deoxythymidine in B6C3F1 mice and F344 rats. Environ. Mol. Mutagen. 2007; 48: 283-298.
9. Gonzalez CM, Larripa I. Genotoxic activity of azidothymidine (AZT) in in vitro systems. Mutat. Res. 1994; 321: 113-118.
10. Bialkowska A, Bialkowski K, Gerschenson M, et al. Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'--deoxythymidine (AZT). Carcinogenesis. 2000; 21: 1059-1062.
11. IARC. IARC monographs on the evaluation of carcinogenic risks to humans: some antiviral and antineoplastic drugs, and other pharmaceutical agents. IARC. 2000; 76: 1-521.
12. Bishop JB, Tani Y, Witt K, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol. Sci. 2004; 81: 512-517.
13. Von Tungeln LS, Dobrovolsky VN, Bishop ME, et al. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. Mutagenesis. 2004; 19: 307-311.
14. Ji HJ, Rha SY, Jeung HC, et al. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res. Treat. 2005; 93: 227-236.
15. Borojerdi JP, Ming J, Cooch C, et al. Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells. Mutat. Res. 2009; 665: 67-74.
16. Desai VG, Lee T, Moland CL, et al. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice. Mitochondrion. 2009; 9: 9-16.
17. Dutra A, Pak E, Wincovitch S, et al. Nuclear Bud Formation: A Novel Manifestation of Zidovudine Genotoxicity. Genome Res. 2010; 128: 105-110.
18. Fang J-L, Beland FA. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol. Sci. 2009; 111: 120-130.
19. Fang J-L, McGarrity LJ, Beland FA. Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis. 2009; 24: 133-141.
20. Humer J, Ferko B, Waltenberger A, et al. Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Res. 2008; 18: 314-321.
21. Cooper DL, Lovett ST. Toxicity and tolerance mechanisms for azidothymidine, a replication gap-promoting agent, in Escherichia coli. DNA Repair. 2011; 10: 260-270.
22. Vazquez-Padua MA, Starnes MC, Cheng YC. Incorporation of 3'-azido-3'-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun. 1990; 2: 55-62.
23. Skalski V, Liu SH, Cheng YC. Removal of anti-humanimmunodeficiency-virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'->5'-exonuclease. Biochem. Pharmacol. 1995; 50: 815-821.
24. Wu Q, Beland FA, Chang CW, et al. XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells. Toxicol. Appl. Pharmacol. 2011; 251: 155-162.
25. Slamenova D, Horvathova E, Bartkova M. Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung fibroblasts by the antiretroviral drug 3'-azido-3'--deoxythymidine. Mutat. Res. 2006; 593: 97-107.
26. Falchetti A, Franchi A, Bordi C, et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J. Bone Miner. Res. 2005; 20: 410-418.
27. Tsai CA, Chen JJ. Multivariate analysis of variance test for gene set analysis. Bioinformatics. 2009; 25: 897-903.
28. Pfeifer AM, Cole KE, Smoot DT, et al. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. USA. 1993; 90: 5123-5127.
29. Avramis VI, Kwock R, Solorzano MM, et al. Evidence of in-vitro development of drug-resistance to azidothymidine in T-lymphocytic leukemia-cell lines (JUKAT E6-1/AZT-100) and in pedia pediatricpathient weith HIV-1 infection. J. Acquir. Immune Defic. Syndr. 1993; 6: 1287-1296.
30. Nyce J, Leonard S, Canupp D, et al. Epigenetic mechanisms of drugresistance: drug-induced DNA hypermethylation and drug-resistance. Proc. Natl. Acad. Sci. USA. 1993; 90: 2960-2964.
31. Wu S, Liu X, Solorzano MM, et al. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. J. Acquir. Immune Defic. Syndr. 1995; 8: 1-9.
32. Groschel B, Kaufmann A, Hover G, Cinatl J, Doerr HW, et al. (2002). 3'-azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochem. Pharmacol. 64, 239-246.
33. Groschel B, Cinatl J, Perigaud C, et al. S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs. Antivir. Res. 2002; 53: 143-152.
34. Han T, Fernandez M, Sarkar M, et al. 2', 3'-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sci. 2004; 74: 835-842.
35. Purevjav E, Nelson DP, Varela JJ, et al. Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc. Toxicol. 2007; 7: 255-263.
36. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005; 19: 15-23.
37. Wu YW, Xiao Q, Jiang YY, et al. Synthesis, in vitro anticancer evaluation, and interference with cell cycle progression of N-phosphoamino acid esters of zidovudine and stavudine. Nucleos. Nucleot. Nucl. 2004; 23: 1797-1811.
38. Roskrow M, Wickramasinghe SN. Acute effects of 3'-azido-3'-- deoxythymidine on the cell-cycle of HL60 cells. Clin. Lab. Haemat. 1990; 12: 177-184.
39. Chandrasekaran B, Kute TE, Duch DS. Synchronization of cells in the S-phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity. Cancer Chemother. Pharmacol. 1995; 35: 489-495.
40. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol. Pharmacol. 1990; 37: 665-670.
41. Lim IK. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J. Cancer Res. Clin. Oncol. 2006; 132: 417-426.
42. Duriez C, Falette N, Audoynaud C, et al. The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene. 2002; 282: 207-214.
43. Zhu J, Chen X. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)/M. Mol. Cell. Biol. 2000; 20: 5602-5618.
44. Castano Z, Vergara-Irigaray N, Pajares MJ, et al. Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int. J. Cancer. 2008; 122: 1512-1520.
45. Momot D, Nostrand TA, Ward Y, et al. Role of nucleotide excision repair (NER) in manifestation of zidovudine (AZT)-induced aneuploidy and centrosomal dysregulation. Environ. Mol. Mutagen. 2010; 51: 704.